Scinai Advances Promising Autoimmune Treatment with New Funding Application and Extended Agreement

Scinai Takes Significant Steps Forward in Immunotherapy Development

On March 2, 2026, Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a prominent player in the biopharmaceutical industry, unveiled two crucial developments that could shift the landscape in treatments for severe autoimmune diseases. The company announced the signing of a Second Amendment to its Binding Option Agreement with PinCell S.r.l. and submitted a revised application seeking €12 million in non-dilutive funding under the European Funds for the Modern Economy (FENG) SMART Path program. This initiative is aimed at advancing their innovative candidate, PC111, through the rigorous phases of human proof of concept.

Expanded Funding Opportunity

Scinai's updated application is designed to secure substantial financial support necessary for its ambitious €15 million integrated research and development program focused on PC111. This fully human monoclonal antibody specifically targets soluble Fas Ligand (sFasL), which has shown promise in treating conditions like pemphigus vulgaris (PV) and Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). As there are currently no FDA-approved therapies for SJS/TEN, the success of the PC111 project could offer a vital breakthrough for patients afflicted by these severe autoimmune disorders.

The anticipated timeline for a funding decision is approximately three to four months, during which Scinai expects key developments to unfold. The strategic significance of this funding cannot be overstated; if awarded, it would enhance Scinai’s ability to maintain financial stability while preventing shareholder dilution throughout the clinical development of PC111.

Aligning Timelines for Success

In conjunction with the funding application, the Second Amendment to the Binding Option Agreement importantly realigns the timelines for Scinai’s option to acquire PinCell S.r.l. The new terms extend the deadline for meeting option conditions to August 31, 2026, and the exercise period for the option to September 30, 2026. This adjustment provides a more structured approach to the acquisition process in tandem with ongoing funding efforts, enhancing the prospects for successful project execution.

CEO Amir Reichman remarked on the operational enhancements, stating, “The revised submission reflects a structurally strengthened innovation framework and a clearly defined translational pathway through human proof of concept. Securing substantial non-dilutive funding at this stage would meaningfully de-risk the PC111 program while maintaining disciplined capital allocation and preserving strategic flexibility.”

Future of PC111 Technology

PC111 represents a first-in-class therapeutic option for autoimmune blistering diseases, underlining its potential as a crucial solution in its field. Given the high unmet medical needs associated with these conditions, if clinical trials yield positive results, Scinai anticipates that the treatment will be eligible for accelerated regulatory pathways, which could expedite its route to market.

The company operates not only as a biopharmaceutical entity but also runs a contract development and manufacturing organization (CDMO), providing key services to biotech and pharmaceutical industries. This dual approach enhances their innovation pipeline and operational capabilities, positioning Scinai as a significant player in immunology-focused development.

With ongoing strategic financing and development initiatives, Scinai Immunotherapeutics is set to make waves within the industry as they pursue next-generation therapies while maintaining strong foundations of operational integrity and financial prudence.

For investors and patients alike, the upcoming months will be pivotal in revealing the future of Scinai and its impactful developments in the world of immunotherapy.